クイックコネクト

CPHI Japan, 2023

Join us to expand your horizons
in the Japanese pharma market
Meet Dr.Reddy’s API team at

CPHI Japan, 2023

Booth 5J-20
19-21 April 2023
Tokyo Big Sight, Tokyo,Japan
Contact Us
Verified

Our Team at
CPHI Japan

left Arrow right Arrow

About CPHI Japan

CPHI Japan is the premier event for the pharmaceutical industry in Japan, providing a platform for international companies to connect and do business with key players in the Japanese market. In its 20th anniversary, the event is expected to attract over 200 exhibitors from across the entire pharmaceutical supply chain, showcasing the latest products, solutions, and innovations in the industry.

Attendees can expect to discover the latest products and services from ingredients, contract services, and biopharma to technology, packaging, and machinery. They will also have the opportunity to meet and network with industry leaders, search for potential partners, and arrange meetings with potential partners online through the event's chat service.

Whether you are a large multinational corporation or a small start-up, CPHI Japan provides the perfect platform to expand your horizons in the Japanese pharmaceutical market. Join us at the event and take advantage of the unique opportunities to connect and grow your business.

About Dr.Reddy’s API Business

We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.

Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.

Sustainability

Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.

Sustainability

Our Achievement

Manufacturing Location

Dr. Reddy’s API Manufacturing Locations

Company

 

Contact Us

© 2023 Dr. Reddy’s Laboratories Ltd. All rights reserved.

免責事項

製品またはサービスへの参照を含むこのカタログの情報は、販売の申し出を構成するものではなく、販売の申し出を表すものとして解釈されるものではありません。有効な特許で保護された製品は、商用目的で提供または提供されません。ただし、そのような規制上の免除が存在する場合は、規制当局への提出を目的として、そのような製品の調査数量が提供される場合があります。購入者は、それぞれの市場の特許シナリオを独自に評価する必要があり、すべての特許関連の責任を負うものとします。インドで有効な特許に基づいて保護されている製品は、商用利用はできませんが、セクション 107A の目的には利用できます。

製品またはサービスへの参照を含むこのカタログの情報は、販売の申し出を構成するものではなく、販売の申し出を表すものとして解釈されるものではありません。有効な特許で保護された製品は、商用目的で提供または提供されません。ただし、そのような規制上の免除が存在する場合は、規制当局への提出を目的として、そのような製品の調査数量が提供される場合があります。購入者は、それぞれの市場の特許シナリオを独自に評価する必要があり、すべての特許関連の責任を負うものとします。インドで有効な特許に基づいて保護されている製品は、商用利用はできませんが、セクション 107A の目的には利用できます。